Physician profile
Donald Foon Lum
NPI 1376535724
$319,678.30
in general payments reported to CMS, 2019-2025
10 companies · $87K in 2025
The $87K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $13K · 2021: $18K · 2022: $28K · 2023: $49K · 2024: $109K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $203K · Travel and Lodging: $29K · Consulting Fee: $6,400 · Food and Beverage: $6,204 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $203,019.36 |
| Travel and Lodging | $29,491.44 |
| Consulting Fee | $6,400.00 |
| Food and Beverage | $6,204.43 |
| Education | $105.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $150,544.13 | 2019-2025 | |
| Janssen Biotech, INC. | $118,266.20 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $30,423.08 | 2021-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $14,233.64 | 2019-2025 | Entyvio |
| Eli Lilly and Company | $5,716.62 | 2024 | Omvoh |
| Pfizer INC. | $287.46 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.00 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $34.83 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | |
| Lilly USA, LLC | $25.64 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Lum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.